Neuromodulation devices to treat Parkinson’s and other chronic diseases show positive results in patients
Neuromodulation device market has seen a steady growth in the last decade. The market size has grown owing to the wide array of medical applications in chronic pain, epilepsy, tremor, and migraine. The rise in geriatric population worldwide has also contributed to the expansion of the neuromodulation device market. The technology has been adopted on a larger scale in the developed regions, such as U.S., Canada, and Europe. Technological advancements and developments in the field of neuromodulation in the aforementioned regions has led to a higher adoption rate. Developing countries such as China and India are gradually embracing new innovations in the field of neuromodulation. The true potential of neuromodulation devices has not been recognized yet as the technology is still at a nascent stage. A report that provides valuable insight on the neuromodulation devices market such as market share, size, and growth has been published by Allied Market Research recently.
Neuromodulation devices for Parkinson’s disease
It is estimated that around 10 million people suffer from Parkinson’s disease worldwide. The cost to curb the disease is high and often it becomes impossible for patients to afford the required treatment. Till date, there is no real cure to treat Parkinson’s. However, major breakthroughs in the medical field have shown promising results and soon we might see a full proof treatment that cures the disease completely.
The symptoms include slow movements, tremors, cerebral impairment, and rigidity. Neurostimulators are implanted into the brain using the brain stimulation technique. The surgically implanted device helps to deal with tremors and has the potential to eliminate the same altogether. It was first introduced in 1987 but received FDA approval a decade later. Deep brain stimulation has been successful for multiple patients. However, there have been cases that have reported a few side effects such as depression, apathy, euphoria, and hallucinations. There is also a risk of bleeding when a foreign object is inserted in the body. At times, the body rejects entry of foreign objects which is another obstacle that scientists and researchers are working on.
New medications and developments have shown promising results according to Dr. Peter Schmidt, chief mission officer, National Parkinson Foundation. The new medications are still under the testing phase and would require to undergo a few more tests. Nilotinib and Isradipine are a couple of drugs that have delivered positive results and hold a promising future.
In 2011, DaTscan, a radiopharmaceutical agent got the approval from the FDA. It is injected into the patient’s veins and detects the presence of dopamine in the brain. Dopamine is a neurotransmitter that helps the body to function smoothly. The risk of being infected by Parkinson’s increases when the dopamine-producing neurons in the brain start to reduce. According to Dr. Badih Adada, director of Neurology Center at Cleveland Clinic Florida, the test was available only in the United States and Europe and is a commendable advance made in the right direction. The rise in several such inventions and advancements is further driving the neuromodulation device market.
Neuromodulation system to treat over active bladder
There were not many advances made as far as urinary and fecal dysfunction is concerned. Researchers were looking for a ray of hope to deal with the problem. There were a few promising signs but nothing ever materialized in a way so as to help the patients.
Axonics Modulation Technologies, Inc., were the first developers of the rechargeable implantable Sacral Neuromodulation (SNM) System. In June 2016, the company announced that its first patients were successfully implanted in London and the Netherlands. Professor van Kerrebroeck threw some light on the topic and revealed that the small and compact rechargeable SNM System is a big step forward for the patients suffering from the problem and seeking a long-term solution for the same. OAB has affected around 85 million people in U.S and Europe. Sacral Neuromodulation is an effective and reliable treatment that is popular in the developed regions. Around 200,000 patients have been treated with the therapy with positive results. It is the only OAB treatment that has gained importance compared to standard drug therapy.
Neuromodulation device market has seen a steady growth in the last decade. The market size has grown owing to the wide array of medical applications in chronic pain, epilepsy, tremor, and migraine. The rise in geriatric population worldwide has also contributed to the expansion of the neuromodulation device market. The technology has been adopted on a larger scale in the developed regions, such as U.S., Canada, and Europe. Technological advancements and developments in the field of neuromodulation in the aforementioned regions has led to a higher adoption rate. Developing countries such as China and India are gradually embracing new innovations in the field of neuromodulation. The true potential of neuromodulation devices has not been recognized yet as the technology is still at a nascent stage. A report that provides valuable insight on the neuromodulation devices market such as market share, size, and growth has been published by Allied Market Research recently.
Neuromodulation devices for Parkinson’s disease
It is estimated that around 10 million people suffer from Parkinson’s disease worldwide. The cost to curb the disease is high and often it becomes impossible for patients to afford the required treatment. Till date, there is no real cure to treat Parkinson’s. However, major breakthroughs in the medical field have shown promising results and soon we might see a full proof treatment that cures the disease completely.
The symptoms include slow movements, tremors, cerebral impairment, and rigidity. Neurostimulators are implanted into the brain using the brain stimulation technique. The surgically implanted device helps to deal with tremors and has the potential to eliminate the same altogether. It was first introduced in 1987 but received FDA approval a decade later. Deep brain stimulation has been successful for multiple patients. However, there have been cases that have reported a few side effects such as depression, apathy, euphoria, and hallucinations. There is also a risk of bleeding when a foreign object is inserted in the body. At times, the body rejects entry of foreign objects which is another obstacle that scientists and researchers are working on.
New medications and developments have shown promising results according to Dr. Peter Schmidt, chief mission officer, National Parkinson Foundation. The new medications are still under the testing phase and would require to undergo a few more tests. Nilotinib and Isradipine are a couple of drugs that have delivered positive results and hold a promising future.
In 2011, DaTscan, a radiopharmaceutical agent got the approval from the FDA. It is injected into the patient’s veins and detects the presence of dopamine in the brain. Dopamine is a neurotransmitter that helps the body to function smoothly. The risk of being infected by Parkinson’s increases when the dopamine-producing neurons in the brain start to reduce. According to Dr. Badih Adada, director of Neurology Center at Cleveland Clinic Florida, the test was available only in the United States and Europe and is a commendable advance made in the right direction. The rise in several such inventions and advancements is further driving the neuromodulation device market.
Neuromodulation system to treat over active bladder
There were not many advances made as far as urinary and fecal dysfunction is concerned. Researchers were looking for a ray of hope to deal with the problem. There were a few promising signs but nothing ever materialized in a way so as to help the patients.
Axonics Modulation Technologies, Inc., were the first developers of the rechargeable implantable Sacral Neuromodulation (SNM) System. In June 2016, the company announced that its first patients were successfully implanted in London and the Netherlands. Professor van Kerrebroeck threw some light on the topic and revealed that the small and compact rechargeable SNM System is a big step forward for the patients suffering from the problem and seeking a long-term solution for the same. OAB has affected around 85 million people in U.S and Europe. Sacral Neuromodulation is an effective and reliable treatment that is popular in the developed regions. Around 200,000 patients have been treated with the therapy with positive results. It is the only OAB treatment that has gained importance compared to standard drug therapy.
